Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status

Invernizzi, Pietro; Battezzati, Pier Maria; Crosignani, Andrea; Zermiani, P.; Bignotto, Monica; Papa, Nicoletta Del; Zuin, Massimo; Podda, Mauro

doi:10.1046/j.1365-2249.1998.00735.x

Cited by 57 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially the confirmation of the assay on a wide random patient population would be advisable, considering that 30 AMA-negative patients are representative for 600 patients with PBC. Subsequently, several minor autoantigens, [28][29][30] including a vast array of nuclear antigens, 12,31 could be added to the bead panel in the attempt to generate a comprehensive PBC assay or an autoimmune liver assay. The development of such a panel would permit the definition of autoantibody status with a single assay, importantly simplifying and accelerating diagnostics in autoimmune liver conditions.…”

Section: Discussionmentioning

confidence: 99%

A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis

et al. 2007

View full text Add to dashboard Cite

The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly directed and specific self-reacting antibody in human immunopathology. Originally, antimitochondrial antibodies (AMAs) were detected by indirect immunofluorescence (IIF) and found in approximately 90% of well-documented patients with PBC. The introduction of recombinant autoantigens and the use of immunoblotting have increased the sensitivity and specificity of AMAs, and they are now considered positive in approximately 95% of patients with PBC. Clearly, accurate autoantibody detection represents one of the fundamental requirements for reliable diagnostics in autoimmunity. To address the 5% of AMA-negative patients with PBC, we have generated and validated a bead assay for the detection of AMA. We enrolled 120 patients with PBC, including a non-random group of 30 rigorously proven AMA-negative patients, 50 healthy subjects, and 74 controls with autoimmune diseases ( T he presence of circulating anti-mitochondrial antibodies (AMAs) represents a key diagnostic feature of primary biliary cirrhosis (PBC). Using highly sensitive assays with recombinant antigens, up to 95% of PBC patients have sera autoantibodies directed against the ubiquitous 2-oxo-acid-dehydrogenase complexes involved in mitochondrial energy metabolism. AMA positivity with its unique prevalence rate among autoimmune diseases 1 represents one of the three diagnostic criteria for PBC, the others being liver histology compatible with the disease and a persistent elevation of alkaline phosphatase. 2 Approximately 5% of well-documented PBC patients do not react with any of the mitochondrial antigens using currently available assays. Over the past decade, the "AMA-negative" population has been progressively reduced in our laboratory by the development of more sensitive detection techniques. 3 Nonetheless, the persistence of some AMA-negative subjects raises the question of whether these patients represent a subpopulation with distinct clinical features or simply have antibody titers and specificities undetectable with available technology. 4 Recent technological advances have led to the development of increasingly automated detection methods associated with more rapid, accurate, and reliable assaying, 5 which could address the question. The From the

show abstract

Section: Discussionmentioning

confidence: 99%

A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Ninety-six patients were studied: 33 rheumatoid arthritis (RA), 8 psoriatic arthritis (PA), 8 ankylosing spondilitis (AS), 23 Systemic Lupus Erythematosus (SLE), 10 Sjogren Syndrome (SS), and 14 SSc. Salient demographic and clinical characteristics of the study population are reported in Table I.…”

Section: Methodsmentioning

confidence: 99%

Antibodies to Carbonic Anhydrase in Patients with Connective Tissue Diseases: Relationship with Lung Involvement

Caccavo

Afeltra

Rigon

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The aim of this study is to evaluate the presence of antibodies to carbonic anhydrase I and/or II (ACAI and ACAII) in patients affected by connective tissue diseases (CTD) and to investigate their association with lung involvement evaluated by High resolution CT scan (HRCT). Ninety-six patients affected by CTD were studied, i.e, 33 rheumatoid arthritis (RA), 8 psoriatic arthritis (PA), 8 ankylosing spondilitis (AS), 23 Systemic Lupus Erythematosus (SLE), 10 Sjogren Syndrome (SS), and 14 Systemic Sclerosis (SSc). ACA were detected by ELISA. The lung involvement was evaluated by means of a previously described HRCT score. According to a receiver operator characteristic curve, patients were divided into those with HRCT score z 10 and those with HRCT score < 10, where HRCT score ;::: 10 was predictive of interstitial lung disease. ACAI and/or ACAII were detected in 30/96 patients (31.2%) (P

show abstract

“…It is common to associate CP with several autoimmune diseases, such as primary biliary cirrhosis (PBC) or Sjögren syndrome (SS) [6]. Furthermore, one theory contends that those diseases might be manifestations in different organs of an autoimmune reaction against a common autoantigen.…”

Section: Introductionmentioning

confidence: 99%

Low-Avidity Antibodies to Carbonic Anhydrase-I and -II in Autoimmune Chronic Pancreatitise

Bartolomé

Heras

López-Hoyos

2002

The Scientific World JOURNAL

View full text Add to dashboard Cite

Antibodies (Abs) to carbonic anhydrase (isoforms CA-I and CA-II) have been considered pathogenic factors in the development of autoimmune pancreatitis. Besides, such autoAbs might accelerate the pancreatic damage in alcoholic chronic pancreatitis (CP). The aim of the present study was to evaluate the presence of serum Abs to CA-I and CA-II in CP and the relative affinity of these Abs.Serum anti-CA-I and -CA-II Abs were measured in 89 patients with CP (48 alcoholic and 41 nonalcoholic) by an ELISA technique. The prevalence of those autoAbs in CP was compared with other autoimmune diseases where they have also been found. The presence of other serological manifestations of autoimmunity, such as hypergammaglobulinemia or antinuclear Abs, was determined in CP patients as well.Elevated serum levels of both anti-CA-I (24%) and -CA-II (18%) Abs were observed in CP, although their prevalence was lower than in autoimmune diseases like rheumatoid arthritis (44 and 25%, respectively) or systemic lupus erythematosus (39% for anti-CA-I Abs). Furthermore, these Abs were of low average avidity. On the other hand, a significantly higher proportion of nonalcoholic CP had anti-CA-II Abs with respect to alcoholic CP (15.2 vs. 2.4%, p < 0.05).Anti-CA-I and -CA-II Abs might be helpful in the diagnosis of autoimmune CP, and the detection of the latter Abs seems to discard alcoholic etiology. Although it does not discard any pathogenic role in autoimmune CP, the low-avidity of anti-CA Abs argues against such idea.

show abstract

Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status

Cited by 57 publications

References 33 publications

A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis

A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis

Antibodies to Carbonic Anhydrase in Patients with Connective Tissue Diseases: Relationship with Lung Involvement

Low-Avidity Antibodies to Carbonic Anhydrase-I and -II in Autoimmune Chronic Pancreatitise

Contact Info

Product

Resources

About